These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 20120857

  • 1. [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].
    Li SS, Zhang X, Xu J, Xie L, Qiu Y, Shu X, Tian Y.
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Sep; 23(18):817-20, 823. PubMed ID: 20120857
    [Abstract] [Full Text] [Related]

  • 2. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5930-9. PubMed ID: 15355926
    [Abstract] [Full Text] [Related]

  • 3. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH.
    Cancer; 2007 Dec 15; 110(12):2775-84. PubMed ID: 17948911
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
    Ali S, El-Rayes BF, Sarkar FH, Philip PA.
    Mol Cancer Ther; 2005 Dec 15; 4(12):1943-51. PubMed ID: 16373709
    [Abstract] [Full Text] [Related]

  • 5. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
    Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG.
    Clin Cancer Res; 2013 Mar 01; 19(5):1244-56. PubMed ID: 23422093
    [Abstract] [Full Text] [Related]

  • 6. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
    Chen L, He Y, Huang H, Liao H, Wei W.
    Med Oncol; 2008 Mar 01; 25(2):161-71. PubMed ID: 18172786
    [Abstract] [Full Text] [Related]

  • 7. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6261-9. PubMed ID: 16144930
    [Abstract] [Full Text] [Related]

  • 8. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
    Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN.
    Cancer Res; 2007 Oct 01; 67(19):9380-8. PubMed ID: 17909047
    [Abstract] [Full Text] [Related]

  • 9. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 01; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 10. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 11. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
    Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP.
    Int J Radiat Oncol Biol Phys; 2008 Jan 01; 70(1):203-12. PubMed ID: 17996386
    [Abstract] [Full Text] [Related]

  • 12. Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
    Altundag O, Altundag K, Boruban C, Silay YS.
    Lung Cancer; 2005 Sep 01; 49(3):429. PubMed ID: 16102610
    [No Abstract] [Full Text] [Related]

  • 13. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N, Li H, Su F, Li J, Ma X, Gong P.
    Int J Clin Exp Pathol; 2015 Sep 01; 8(8):9010-20. PubMed ID: 26464643
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS, Chen Z, Klass CM, Zhang X, Shin DM.
    Clin Cancer Res; 2007 May 15; 13(10):3015-23. PubMed ID: 17505004
    [Abstract] [Full Text] [Related]

  • 15. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 16. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
    Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.
    J Thorac Oncol; 2008 Feb 01; 3(2):117-24. PubMed ID: 18303430
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
    Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6155-61. PubMed ID: 16144915
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.